Chris JacobsBuy
Axsome Therapeutics, Inc. · Transaction Jun 16, 2022 · Filed Jul 28, 2022 · $15,001 to $50,000
NASDAQ NMS - GLOBAL MARKET · AXSM
-0.92% · -$1.56 · Vol 894.5K
Market closed · last close 4:00 PM ET · price as of 16:01:39 ET
Axsome Therapeutics Inc
Pharmaceuticals
$168.52
Follow $AXSM
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AXSM by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredSat Oct 10 · market closed · Markets closed · resumes Mon 9:30 ET · AXSM
MethodologyAXSM
Axsome Therapeutics Inc
Sat Oct 10 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
45/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Sat Oct 10 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AXSM moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Axsome Therapeutics Inc
PHARMACEUTICAL PREPARATIONSListed since
2015
Employees
925
Country
US
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$170.18
Day high
$170.64
Day low
$166.12
Previous close
$170.08
52W high
$255.17
-33.96% from high
52W low
$121.15
35% of range
Market cap
$8.8B
EPS
$-3.7593
Beta
0.47
Shares out
52.4M
Volume
894.5K
1.20× rel vol
Avg volume
743.5K
VWAP
$168.85
Price history computed in-house
1W
-5.99%
1M
-20.18%
3M
-27.92%
1Y
+38.46%
YTD
-7.73%
SMA 50 $203.16 · below
SMA 200 $200.36 · below
52W position 35%
AXSM overview
Related filings and maps
Public disclosures
Congress activity in AXSM
1 filers · 1 buys · 0 sells (0 labeled S (partial)) · Jun 16, 2022 to Jun 16, 2022 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-10T21:03:45.253Z
Official filing ↗
Federal contracts
AXSM contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AXSM in this window.
Lobbying spend
AXSM lobbying filings, year to date.
Registered lobbying filings matched to Axsome Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AXSM in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for AXSM.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.